Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Ohe

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
British Journal of Cancer|March 20, 2003
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507I Sekine, Y Nishiwaki, R Kakinuma, et al.
Japanese Journal of Clinical Oncology|March 21, 2002
A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancerK Hotta, I Sekine, T Tamura, et al.
British Journal of Cancer|January 1, 1997
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancerM Ando, K Eguchi, T Shinkai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
ESMO Open|March 23, 2024
Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCMS Watanabe, H Yoshioka, H Sakai, et al.
British Journal of Cancer|July 29, 2004
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerK Goto, I Sekine, Y Nishiwaki, et al.
ESMO Open|February 14, 2022
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patientsK J O'Byrne, K H Lee, S-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2021
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerS Sugawara, J-S Lee, J-H Kang, et al.
Annals of Human Genetics|August 16, 2006
Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differencesK Sai, M Itoda, Y Saito, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
British Journal of Cancer|March 20, 2003
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507I Sekine, Y Nishiwaki, R Kakinuma, et al.
Japanese Journal of Clinical Oncology|March 21, 2002
A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancerK Hotta, I Sekine, T Tamura, et al.
British Journal of Cancer|January 1, 1997
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancerM Ando, K Eguchi, T Shinkai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)K Takeuchi, Y Togashi, Y Kamihara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
ESMO Open|March 23, 2024
Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCMS Watanabe, H Yoshioka, H Sakai, et al.
British Journal of Cancer|July 29, 2004
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerK Goto, I Sekine, Y Nishiwaki, et al.
ESMO Open|February 14, 2022
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patientsK J O'Byrne, K H Lee, S-W Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2021
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerS Sugawara, J-S Lee, J-H Kang, et al.
Annals of Human Genetics|August 16, 2006
Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differencesK Sai, M Itoda, Y Saito, et al.
Pageof 20